Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: An open-label, phase I, single-dose study in healthy men

Drug Metabolism and Disposition

Volumn 43, Issue 2, 2015, Pages 289-297

  Scheers, Ellen ^a   Leclercq, Laurent ^a   De Jong, Jan ^b   Bode, Nini ^c   Bockx, Marc ^a   Laenen, Aline ^a   Cuyckens, Filip ^a   Skee, Donna ^d   Murphy, Joe ^d   Sukbuntherng, Juthamas ^e   Mannens, Geert ^a  

^a Senior Scientific Direc and Fellow Pharmacokinetics Dynamics and Metabolism Janssen RandD   (Belgium)

^b Oncology Clinical Pharmacology   (United States)

^c Pre Clinical Project Development Janssen RandD   (Belgium)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DRUG METABOLITE; IBRUTINIB; PCI 45227; UNCLASSIFIED DRUG; ADENINE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; CARBON; PCI-45227; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; COVALENT BOND; DIARRHEA; DOSIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HYDROXYLATION; DRUG LABELING; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; EPOXIDATION; FIRST PASS EFFECT; HEADACHE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PLASMA HALF LIFE; RADIOACTIVITY; SINGLE DRUG DOSE; SKIN IRRITATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; BLOOD; CHEMISTRY; CLINICAL TRIAL; FECES; HALF LIFE TIME; HYDROLYSIS; HYDROXYLATION; INTESTINAL EXCRETION; INTESTINE ABSORPTION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OXIDATION REDUCTION REACTION; URINARY EXCRETION; URINE;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CARBON RADIOISOTOPES; FECES; HALF-LIFE; HUMANS; HYDROLYSIS; HYDROXYLATION; INTESTINAL ABSORPTION; INTESTINAL ELIMINATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OXIDATION-REDUCTION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RENAL ELIMINATION;

EID: 84921024884     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.060061     Document Type: Article

References (11)

1. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, and Chang BY, et al. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88-94.
2. Brown JR (2014) Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma 55:263-269.
3. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, and Wierda WG, et al. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32-42.
4. de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit H, de Vries R, Jiao J, and Mannaert E (2014) Effect of CYP3A perpetrators on ibrutinib exposure in normal healthy subjects. Clin Pharmacol Ther 95 (Supplement 1): PI-045.
5. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, and Buggy JJ, et al. (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117:6287-6296.
6. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, and Miller RA, et al. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107:13075-13080.
7. International Commission on Radiological Protection (1991) Radiological protection in biomedical research. ICRP Publication 62 Ann ICRP 22:1-28.
8. International Commission on Radiological Protection (2007) Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Ann ICRP 37: 1-332.
9. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, and Wierda WG, et al. (2014) Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15:48-58.
10. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, and Williams ME, et al. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantlecell lymphoma. N Engl J Med 369:507-516.
11. Winer ES, Ingham RR, and Castillo JJ (2012) PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 21: 355-361.